Overview Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies. We concentrate on underserved, chronic medical conditions for which oral administration of a protein therapy has the potential to significantly shift a treatment paradigm. Our pipeline includes differentiated, first-in-class oral peptides targeting PTH(1-34), GLP-1/Glucagon and GLP-2: Currently, most protein therapies are administered via frequent int...
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-27 | 2025-12-31 | 0001178913-26-001797 | EDGAR | 96K words |
| 2025-03-28 | 2024-12-31 | 0001178913-25-001112 | EDGAR | — |
| 2024-03-08 | 2023-12-31 | 0001178913-24-000881 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001178913-23-001272 | EDGAR | — |
| 2022-03-08 | 2021-12-31 | 0001178913-22-000994 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001178913-25-003852 | EDGAR | 20K words |
| 2025-08-08 | 2025-06-30 | 0001178913-25-002702 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0001178913-25-001674 | EDGAR | — |
| 2024-11-08 | 2024-09-30 | 0001178913-24-003558 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001178913-24-002522 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0001178913-24-001683 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001178913-23-003665 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0001178913-23-002834 | EDGAR | — |
| 2023-05-05 | 2023-03-31 | 0001178913-23-001715 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001178913-22-003941 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001178913-22-003056 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001178913-22-001917 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-03 | 0001178913-26-002001 | EDGAR | 18K words |
| 2026-03-27 | 0001178913-26-001792 | EDGAR | — |
| 2026-03-04 | 0001178913-26-000714 | EDGAR | — |
| 2026-02-09 | 0001178913-26-000355 | EDGAR | — |
| 2026-02-04 | 0001178913-26-000300 | EDGAR | — |
| 2025-11-14 | 0001178913-25-003851 | EDGAR | — |
| 2025-08-08 | 0001178913-25-002701 | EDGAR | — |
| 2025-07-28 | 0001178913-25-002484 | EDGAR | — |
| 2025-07-18 | 0001178913-25-002406 | EDGAR | — |
| 2025-05-09 | 0001178913-25-001673 | EDGAR | — |
149 total filings indexed. 122 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001638097 |
| Ticker | ENTX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | L3 |
| Website | https://www.enterabio.com |
| Listed | 2018-06-28 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report